Literature DB >> 32049049

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.

Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung-Min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J Wick, Richard E Cutler, Alshad S Lalani, Richard Bryce, Alan Auerbach, Ariella B Hanker, Carlos L Arteaga.   

Abstract

Entities:  

Year:  2020        PMID： 32049049     DOI： 10.1016/j.ccell.2020.01.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  7 in total

1.  New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.

Authors:  Ana F Castillo; Ulises D Orlando; Paula M Maloberti; Jesica G Prada; Melina A Dattilo; Angela R Solano; María M Bigi; Mayra A Ríos Medrano; María T Torres; Sebastián Indo; Graciela Caroca; Hector R Contreras; Belkis E Marelli; Facundo J Salinas; Natalia R Salvetti; Hugo H Ortega; Pablo Lorenzano Menna; Sergio Szajnman; Daniel E Gomez; Juan B Rodríguez; Ernesto J Podesta
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

2.  Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles.

Authors:  Sandeep Kumar; Subhasis Das; Jingjing Sun; Yixian Huang; Sunil Kumar Singh; Piush Srivastava; Gautam Sondarva; Rakesh Sathish Nair; Navin Viswakarma; Balaji B Ganesh; Lei Duan; Carl G Maki; Kent Hoskins; Oana Danciu; Basabi Rana; Song Li; Ajay Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-12       Impact factor: 12.779

3.  ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance.

Authors:  Jiefeng Huang; Jie Li; Jun Tang; Yushen Wu; Fengsheng Dai; Ziying Yi; Yan Wang; Yunhai Li; Yue Wu; Guosheng Ren; Tingxiu Xiang
Journal:  Int J Biol Sci       Date:  2022-04-04       Impact factor: 10.750

4.  Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.

Authors:  Yaoxiang Tang; Jiadi Luo; Ying Zhou; Hongjing Zang; Yang Yang; Sile Liu; Hongmei Zheng; Jian Ma; Songqing Fan; Qiuyuan Wen
Journal:  BMC Cancer       Date:  2022-05-20       Impact factor: 4.638

5.  Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Authors:  Patricia V Elizalde; Rosalía I Cordo Russo; Santiago Madera; Franco Izzo; María F Chervo; Agustina Dupont; Violeta A Chiauzzi; Sofia Bruni; Ezequiel Petrillo; Sharon S Merin; Mara De Martino; Diego Montero; Claudio Levit; Gabriel Lebersztein; Fabiana Anfuso; Agustina Roldán Deamicis; María F Mercogliano; Cecilia J Proietti; Roxana Schillaci
Journal:  Cell Death Dis       Date:  2022-05-09       Impact factor: 9.685

6.  A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations.

Authors:  Jing Ma; Xuelu Li; Qianran Zhang; Ning Li; Siwen Sun; Shanshan Zhao; Zuowei Zhao; Man Li
Journal:  Transl Oncol       Date:  2022-05-03       Impact factor: 4.803

7.  Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer.

Authors:  William W Feng; Manabu Kurokawa
Journal:  Cancer Drug Resist       Date:  2020-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.